Investors
Corporate Profile
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
Click here to view the Ocugen 2022 R&D Day event
Ocugen News
September 29, 2023 Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 27, 2023 Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 21, 2023 Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
Corporate Presentation
Events
Chardan's 7th Annual Genetic Medicines Conference October 2, 2023 at 1:30 PM EDT
Cantor Global Healthcare Conference September 26, 2023 at 1:00 PM EDT